STATEMENT: AtomVie Global Radiopharma collaborates with RLS and UPPI to strengthen its radiotherapeutic distribution network

(Information sent by the signatory company).

STATEMENT: AtomVie Global Radiopharma collaborates with RLS and UPPI to strengthen its radiotherapeutic distribution network

(Information sent by the signatory company)

- AtomVie Global Radiopharma collaborates with RLS and UPPI to strengthen its existing radiotherapeutic distribution network in the United States

HAMILTON, ON, Feb. 22, 2024 /PRNewswire/ -- AtomVie Global Radiopharma Inc. (AtomVie), a leading radiopharmaceutical contract development and manufacturing organization (CDMO), is proud to announce strategic collaborations with RLS Radiopharmacies and UPPI LLC . (UPPI), two industry leaders in radiopharmacy and logistics. This strategic move is set to enhance AtomVie's logistics capabilities within the United States, ensuring widespread distribution of high-quality radiopharmaceuticals by implementing RLS and UPPI as key partners within AtomVie's existing distribution network in the United States. AtomVie specializes in GMP manufacturing and global distribution of radiopharmaceuticals, RLS is the only Joint Commission accredited radiopharmacy network in the United States, owns and operates 31 radiopharmacies covering more than 80% of the US population, and UPPI, organized as a group purchasing organization. (GPO), provides extensive capabilities in logistics and distribution.

Radiopharmaceuticals play a critical role in precision medicine solutions, providing innovative and promising treatments for various cancer indications. Recognizing the logistical challenges associated with radiopharmaceuticals, given their short half-life and the critical importance of timely administration; AtomVie, together with RLS and UPPI, will strengthen their distribution capabilities and enable life-saving treatments to reach more patients.

"Our commitment to transforming patients' lives through high-quality radiopharmaceuticals is at the core of this partnership with RLS and UPPI," said Bruno Paquin, CEO of AtomVie. He added: "These collaborations strengthen our ability to deliver critical radiopharmaceuticals to more locations, ensuring timely access for patients who depend on the products. These partnerships not only meet current demand but position us for future growth, as we expand significantly increased our manufacturing capacity and added commercial-scale capabilities.

Under the agreements, AtomVie will leverage RLS and UPPI's extensive radiopharmacy network as the companies aim to rapidly deliver radiopharmaceuticals to healthcare providers.

Stephen Belcher, CEO of RLS, expressed confidence in the partnership's impact on patient care, saying: "Radiopharmaceuticals begin to decay very quickly and it is essential that they reach patients in a safe and timely manner. That is why this partnership is so important. We are the experts in the last mile, and by adding our radiopharmacies to its network, AtomVie can ensure that its portfolio of life-enhancing therapeutic and diagnostic radiopharmaceuticals arrives at the right place at the right time, every time. ".

John Witkowski, President of UPPI, highlighted the impact of the partnership, which promotes greater accessibility and greater well-being for people, saying: "This partnership is an important step forward in improving access to radioisotope-based therapies and diagnostics that "They save lives. It reflects our joint commitment to providing precision medicine solutions for patients across the country."

As leaders in their respective fields, AtomVie, RLS and UPPI bring unique expertise to this strategic partnership, offering seamless radiopharmaceutical solutions and emphasizing their collective goal of revolutionizing patient care by offering consistent access to high-quality radiopharmaceutical options nationwide.

About AtomVie Global Radiopharma Inc.

AtomVie Global Radiopharma Inc. (AtomVie) is a leading global CDMO for GMP manufacturing and global distribution of clinical and commercial radiopharmaceuticals. AtomVie offers the full range of scientific, technical, regulatory, quality, logistical and commercial expertise combined with specialized infrastructure for the development of radiopharmaceuticals from clinical studies to the commercial market. AtomVie currently serves international clients conducting studies in over 20 countries worldwide. AtomVie is currently constructing a >70,000 square foot, state-of-the-art, scalable facility in Hamilton Ontario that will be ready in late 2024. For more information, visit

About RLS Inc.

RLS Radiopharmacies (Radioisotope Life Sciences) has one of the largest radiopharmacy networks in the United States, with 31 radiopharmacies covering more than 80% of the population. The company also offers a broad portfolio of diagnostic and therapeutic radiopharmaceutical products. RLS strives to supply the highest quality radiopharmaceuticals in the industry by dispensing 100% injectable unit dose products in clean rooms built to ISO 1644-1 specifications. In support of its commitment to quality, RLS provides customized solutions and exceptional service to more than 1,500 customers. For more information, visit


Founded in 1998, UPPI has become a leader in traditional nuclear medicine and the rapidly growing field of theranostics. Representing more than 60 independent and institutional operating sites nationwide, UPPI provides its members with national strength in purchasing relationships as well as access to customizable local programs that promote industry professionalism. For more information, visit:

Photo -

View original content: